For years, Priya, a 28-year-old software engineer from Bengaluru, dismissed her symptoms as "weak digestion" — an explanation her family readily accepted. Frequent loose stools, cramping before meals, occasional blood in the toilet bowl she quietly ignored. It took a near-hospitalisation with severe anaemia to finally get a diagnosis: ulcerative colitis, a form of inflammatory bowel disease (IBD). Her gastroenterologist told her she was part of a worrying new trend.
India is now the fastest-growing country in the world for IBD incidence, topping Southeast Asia. Historically seen as a disease of Western populations, IBD is rapidly becoming an Indian healthcare challenge — driven by urbanisation, changing dietary patterns, antibiotic overuse, and shifting gut microbiome. Yet awareness remains startlingly low, and the average Indian patient waits 2–3 years from first symptoms to correct diagnosis. This guide is designed to close that gap.
What Is Inflammatory Bowel Disease (IBD)?
Inflammatory bowel disease (IBD) is a group of chronic conditions in which the immune system mistakenly attacks the lining of the digestive tract, causing ongoing inflammation. IBD is not the same as irritable bowel syndrome (IBS) — IBS involves no inflammation or structural damage to the gut, while IBD causes real, measurable injury to intestinal tissue.
IBD has two main forms:
Ulcerative Colitis (UC)
- Inflammation is continuous and limited to the large intestine (colon) and rectum
- Begins in the rectum and can extend upward through the colon
- Causes ulcers (sores) in the colon lining
- Symptoms include bloody diarrhoea, urgency, and mucus in stool
- Commoner form in India, particularly in north India
Crohn's Disease (CD)
- Inflammation can affect any part of the digestive tract, from mouth to anus
- Occurs in patches with unaffected "skip areas" between inflamed sections
- Can penetrate the full thickness of the gut wall, leading to fistulas, abscesses, and strictures
- Symptoms are more variable and can include abdominal pain, diarrhoea, weight loss, and perianal disease
- More prevalent in south India relative to UC
IBD-Unclassified (IBDU)
Some patients have features of both UC and Crohn's, and cannot be definitively categorised. This is termed IBD-unclassified or indeterminate colitis.
IBD in India: A Rapidly Changing Landscape
The epidemiology of IBD in India is dramatically different from what it was two decades ago — and it is changing fast:
- Rising incidence: IBD incidence in India has been climbing steadily since the 1990s, and is now the highest in Southeast Asia
- Younger patients: The Indian IBD profile skews younger than the Western pattern. The highest burden is in children, adolescents, and adults under 40
- Men more affected than women: Unlike in the West, Indian IBD shows a male predominance
- Urban-rural divide: IBD is 3-4 times more common in urban India than rural areas, reflecting the "hygiene hypothesis" and dietary westernisation
- North-South pattern: UC predominates in the north; Crohn's disease is proportionately more common in south India
- Underdiagnosis: Because symptoms overlap with infections (like amoebic colitis, TB, and typhoid — all endemic in India), IBD is frequently misdiagnosed or missed entirely
What is driving this increase? Researchers point to: antibiotic overuse altering gut microbiome, low dietary fibre in urbanised diets, increased food processing, reduced childhood infections (the hygiene hypothesis), genetic susceptibility variants that appear more prevalent in certain Indian populations, and stress.
Recognising the Symptoms of IBD
The symptoms of IBD can be subtle in the early stages and overlap with other conditions common in India (infections, IBS, food intolerance). Key warning signs to watch for:
Gut (Intestinal) Symptoms
- Persistent or recurrent diarrhoea lasting more than 4 weeks
- Blood or mucus in stool — this is never normal and always requires medical evaluation
- Abdominal cramping and pain, especially before or during defecation
- Urgency — a sudden, intense need to defecate
- Tenesmus — feeling of incomplete bowel emptying even after passing stool
- Nocturnal diarrhoea — waking at night to pass stool (a red flag feature not seen in IBS)
Systemic (Whole-Body) Symptoms
- Unexplained weight loss (>5% body weight over 3 months)
- Persistent fatigue and weakness (often from anaemia)
- Low-grade fever during flares
- Loss of appetite
Extra-Intestinal Manifestations (EIMs)
Up to 40% of IBD patients develop problems outside the gut. These are not side effects of medication — they are part of the disease itself:
| System | Manifestations |
|---|---|
| Joints | Peripheral arthritis (large joints), ankylosing spondylitis |
| Eyes | Uveitis (red, painful eye), episcleritis |
| Skin | Erythema nodosum (tender red nodules on shins), pyoderma gangrenosum |
| Liver/bile ducts | Primary sclerosing cholangitis (PSC) — especially in UC |
| Bones | Osteoporosis, vitamin D and B12 deficiency |
| Blood | Anaemia, clotting problems (deep vein thrombosis risk is elevated) |
Important: EIMs sometimes appear before gut symptoms, particularly joint pain and eye inflammation. These may be misattributed to other causes for months or years before IBD is diagnosed.
How IBD Is Diagnosed in India
IBD diagnosis requires a combination of clinical evaluation, blood tests, stool tests, imaging, and endoscopy. There is no single definitive blood test.
Blood Tests
| Test | What It Tells You | Cost (Private) |
|---|---|---|
| Full blood count (CBC) | Anaemia from blood loss; raised WBC during infection/inflammation | ₹300–600 |
| CRP (C-reactive protein) | Elevated in active IBD; helps monitor disease activity | ₹300–500 |
| ESR | Non-specific inflammation marker | ₹100–200 |
| Serum albumin | Low in malnutrition from active Crohn's | ₹200–400 |
| Iron studies (ferritin, serum iron) | Iron-deficiency anaemia is common | ₹400–800 |
| Vitamin B12, Vitamin D | Often deficient, especially in Crohn's affecting the ileum | ₹400–800 each |
| LFT (liver function tests) | Screen for hepatic EIMs | ₹400–700 |
| ANCA, ASCA serology | Distinguishes UC from Crohn's in some cases; specialist use | ₹1,500–3,000 |
You can track all these results over time with MedicalVault's trend analysis feature, which is particularly useful for IBD patients who require frequent monitoring.
Stool (Faecal) Tests
| Test | Purpose | Cost |
|---|---|---|
| Faecal calprotectin | Most useful non-invasive test for IBD — a protein released by inflamed gut lining; helps distinguish IBD from IBS | ₹1,500–3,500 |
| Stool routine + microscopy | Rules out infections (amoeba, giardia, helminthes) | ₹150–400 |
| Stool culture + sensitivity | Rules out bacterial infection (Salmonella, E. coli) | ₹400–800 |
| Stool for C. difficile toxin | Important before starting steroids | ₹800–1,500 |
Faecal calprotectin is increasingly available at major Indian diagnostic labs (Dr. Lal PathLabs, SRL, Metropolis) and is a critical non-invasive first step if IBD is suspected.
Endoscopy: The Gold Standard
Colonoscopy with biopsies is required to confirm IBD diagnosis and distinguish UC from Crohn's. It:
- Visually shows inflammation, ulcers, and the pattern of disease
- Allows tissue biopsies to confirm diagnosis and rule out intestinal TB (a crucial distinction in India)
- Maps the extent of disease (which guides treatment intensity)
For Crohn's disease, upper GI endoscopy and small bowel imaging (MRI enterography, capsule endoscopy) may also be required to assess small intestine involvement.
Cost in India: Colonoscopy ranges from ₹5,000–15,000 at private hospitals; available free at government medical colleges.
Distinguishing IBD from Intestinal TB: India's Unique Challenge
This is critical in India. Intestinal tuberculosis (TB) and Crohn's disease can look virtually identical on colonoscopy, histology, and imaging. Getting this distinction wrong is dangerous:
- Treating IBD as TB delays proper treatment and allows gut damage to progress
- Treating TB as Crohn's (especially with immunosuppressants) can cause TB to disseminate fatally
Indian gastroenterologists typically perform a diagnostic trial of anti-TB therapy (2–3 months) in ambiguous cases before confirming Crohn's disease. A tuberculin skin test (Mantoux), IGRA (QuantiFERON-TB Gold), and careful histology are used to guide this decision.
Treatment of IBD in India
IBD is a chronic, relapsing-remitting condition. The goal of treatment is remission — eliminating active inflammation so the gut can heal — and then maintenance — preventing relapse. Treatment has evolved dramatically in the last decade.
Step-Up Treatment Approach
Treatment is individualised based on disease type, extent, severity, and patient factors. Indian gastroenterologists generally follow a step-up strategy:
For Mild-Moderate Ulcerative Colitis
- 5-ASA drugs (mesalamine/sulphasalazine): First-line treatment for UC; reduces and maintains remission; available in oral and rectal (suppository/enema) forms
- Indian brands: Asacol, Pentasa, Mesacol, Salazopyrin (sulphasalazine)
- Cost: ₹500–2,500/month depending on dose and form
For Moderate-Severe Disease or Crohn's
- Corticosteroids (prednisolone, budesonide): Rapidly suppress inflammation during flares; not for long-term use due to side effects (osteoporosis, diabetes, weight gain)
- Immunomodulators (azathioprine, 6-mercaptopurine, methotrexate): Reduce immune overactivity; take 3–6 months to achieve full effect; require regular blood monitoring (CBC, LFT)
- Biologic drugs: The most powerful available treatment, targeted at specific inflammation pathways
Biologic Therapies Available in India
Biologics have transformed IBD outcomes globally and are increasingly accessible in India through:
| Drug | Class | Route | Available in India | Approx. Monthly Cost |
|---|---|---|---|---|
| Infliximab (Remicade, Remsima, BioFLAGship) | Anti-TNF | IV infusion | Yes (biosimilars available) | ₹8,000–50,000 |
| Adalimumab (Humira, Exemptia, Adfrar) | Anti-TNF | Subcutaneous injection | Yes (biosimilars available) | ₹10,000–60,000 |
| Vedolizumab (Entyvio, Entyvio biosimilar) | Gut-selective anti-integrin | IV infusion | Yes | ₹40,000–80,000 |
| Ustekinumab (Stelara) | Anti-IL-12/23 | IV/SC | Yes | ₹45,000–90,000 |
| Tofacitinib (Xeljanz) | JAK inhibitor (oral) | Oral | Yes | ₹30,000–60,000 |
Biosimilars (copies of biologics after patent expiry) have significantly brought down costs in India. Several Indian pharmaceutical companies — including Cipla, Cadila, and Intas — produce biologics at substantially reduced cost.
Some patients can access biologic therapy through government schemes, corporate hospital financial assistance programmes, or manufacturer patient assistance programmes. Discuss options with your gastroenterologist.
Surgery
Surgery may be necessary for:
- UC: Severe disease unresponsive to medical therapy; colon cancer arising in long-standing UC; toxic megacolon
- Crohn's: Bowel strictures causing obstruction; fistulas; abscesses; severe perianal disease
- Surgery for UC can be curative (removal of the colon eliminates UC); surgery for Crohn's is not curative as disease can recur
Diet and IBD in India
Diet does not cause IBD, but dietary choices profoundly affect symptom control during flares. Indian dietary guidance:
During a flare:
- Reduce insoluble fibre: Avoid whole grains, raw vegetables, maize roti; shift to rice, white bread, idli, dosa
- Avoid high-fat foods that can worsen diarrhoea
- Avoid milk if lactose-intolerant (common during active disease)
- Small, frequent meals rather than three large meals
- Adequate oral rehydration (ORS or coconut water for mild dehydration)
During remission:
- Gradually reintroduce fibre-rich foods (dal, sabzi, fruits)
- Maintain nutritional adequacy — Crohn's patients are particularly at risk of malnutrition
- Fermented foods (dahi, buttermilk, idli, dosa) support gut microbiome health
- Limit processed foods, fast food, and high-sugar drinks linked to IBD flares
There is no "one-size-fits-all IBD diet" — individual food triggers vary considerably. Keeping a food and symptom diary is extremely useful.
Monitoring IBD Over Time
IBD requires lifelong monitoring because:
- Disease extent and activity change over time
- Long-standing UC (>8 years) increases colon cancer risk (surveillance colonoscopies every 1–3 years recommended)
- Medications like azathioprine require regular CBC and LFT monitoring
- Biologic drugs require checks for latent TB (before starting), hepatitis B status, and blood counts
Tracking all reports — colonoscopy findings, blood tests, infusion records — in one place is invaluable for a chronic condition like IBD. Upload your reports to MedicalVault, share them with your gastroenterologist before appointments, and use trend tracking to monitor your CRP, haemoglobin, and calprotectin over time.
Mental Health and IBD
Living with IBD takes a psychological toll that is frequently under-acknowledged in Indian families:
- Rates of anxiety and depression in IBD patients are 2-3 times higher than the general population
- Fear of accidents ("accidents") leads many patients to limit social outings, travel, and work
- Managing IBD within Indian family and workplace contexts often involves stigma and misunderstanding
- Psychotherapy (especially cognitive behavioural therapy, CBT) and peer support groups improve quality of life in IBD
If you or a family member is struggling with the emotional burden of IBD, discuss it openly with your gastroenterologist. Many major Indian hospital IBD programmes now include dedicated psychological support as standard care.
Key Takeaways
- IBD (ulcerative colitis and Crohn's disease) is rising rapidly in India — the country now has the highest IBD incidence in Southeast Asia
- UC is more common in north India; Crohn's disease is relatively more common in south India
- IBD is not IBS — it causes real, measurable inflammation and requires medical management
- Blood in stool, nocturnal diarrhoea, and symptoms lasting more than 4 weeks always require medical evaluation
- Faecal calprotectin is a useful non-invasive initial test; colonoscopy with biopsy is the diagnostic gold standard
- Distinguishing IBD from intestinal TB is a critical and uniquely Indian diagnostic challenge — always see a gastroenterologist with experience in this area
- Biologics (including affordable biosimilars) have transformed outcomes for moderate-severe IBD
- Lifelong monitoring is essential — MedicalVault helps track test reports, trends, and treatment history for this chronic condition
- Mental health support is as important as physical treatment for long-term quality of life
Always consult a gastroenterologist for IBD diagnosis and management. Self-medication or misdiagnosis can lead to serious, preventable harm.